DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,916,582 Stevenson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,916,582 Stevenson Et Al USOO5916582A United States Patent (19) 11 Patent Number: 5,916,582 Stevenson et al. (45) Date of Patent: Jun. 29, 1999 54 AQUEOUS FORMULATIONS OF PEPTIDES WO95/O1183 1/1995 WIPO. WO95/04540 2/1995 WIPO. 75 Inventors: Cynthia L. Stevenson, Mountain View; WO96/07398 3/1996 WIPO. Sally A. Tao, San Jose; Steven J. WO97/27840 8/1997 WIPO. Prestrelski, Mountain View; James B. OTHER PUBLICATIONS Eckenhoff, deceased, late of Los Altos, by Bonnie J. Eckenhoff, Jeremy C. Fu Lu, et al., “Percutaneous Absorption Enhancement of Wright, Los Altos; John J. Leonard, Leuprolide”, Pharmaceutical Research, 9/12, pp. Jr., Cupertino, all of Calif. 1575-1576 (1992). Helm, et al., “Stability of Gonadorelin and Triptorelin in 73 Assignee: ALZA Corporation, Palo Alto, Calif. Aqueous Solution”, Pharmaceutical Research, 7/12, pp. 1253–1256 (1990). 21 Appl. No.: 08/874,694 Johnson, et al., “Degredation9. of the LH-RHAnalog9. Nafare lin Acetate in Aqueous Solution”, Int. J. of Pharmaceutics, 22 Filed: Jun. 13, 1997 31, pp. 125-129 (1986). O O Okada, et al., “Preparation of Three-Month Depot Injectable Related U.S. Application Data MicroSpheres of Leuprorelin Acetate Using Biodegradable Polymers”, Pharmaceutical Research, 11/8, pp. 1143–1147 60 Provisional application No. 60/021,199, Jul. 3, 1996. (1994) (51) Int. Cl." ........................................................ A61F 2/02 Okada, et al., “New Degradation Product of 52 U.S. Cl. ............................................. 424/423; 424/426 Des-Glv'-NH-LH-RH-Ethvlamidey 2 y (Fertirelin) in AqueC 58 Field of Search ...................................... 424/423,426 ous Solution", J. of Pharmaceutical Sciences, 80/2, pp. s 167–170 (1991). 56) References Cited Oyler, et al., “Characterization of the Solution Degradation Products of Histrelin, a Gonadotropin Releasing Hormone U.S. PATENT DOCUMENTS (LH/RH) Agonist”, J. of Pharmaceutical Sciences, 80/3, pp. 3,914,412 10/1975 Gendrich et al. ....................... 424,177 271-275 (1991). 4,547,370 10/1985 Roeske ...................................... 514/15 4,661,472 4/1987 Rivier et al. .............................. 514/15 (List continued on next page.) 4,689,396 8/1987 Roeske et al. 530/313 Primary Examiner—Carlos A. Azpuru 2. S. retal.".3. Attorney, Agent, or Firm-Pauline Ann Clarke; Stephen F. 5,057,3182 - - -2 10/1991 Magruderagruder et al. ... - - - E. Stone; Mary Ann Dillahunty 5,110,596 5/1992 Magruder et al. ... ... 424/438 57 ABSTRACT 5,198,533 3/1993 Schally et al. ... ... 530/313 5,413,990 5/1995 Haviv et al. .............................. 514/15 This invention relates to stable liquid aqueous formulations (List continued on next page.) of peptide compounds at high concentrations. These stable page. formulations comprise at least about 10% peptide in water. FOREIGN PATENT DOCUMENTS They may be Stored at elevated temperatures for long periods of time and are especially useful in implantable wo...I RE Span Pat. Off. delivery devices for long term delivery of drug. WO94/1902O 9/1994 WIPO. WO95/OO168 1/1995 WIPO. 12 Claims, 5 Drawing Sheets Peptide O.O 1O. O. 2O, O 3O.O 4OO Time (min) 5,916,582 Page 2 U.S. PATENT DOCUMENTS Toguchi, “Pharmaceutical Manipulation of Leuprorelin Acetate to Improve Clinical Performance”, J. of Intl. Medi 5,480,868 1/1996 Kamei et al. ............................. 514/15 5,482.931 1/1996 Harris et al. .............................. 514/15 cal Research, 18, pp. 35-41 (1990). 5,498.598 3/1996 Harris ........................................ 514/11 OTHER PUBLICATIONS Factrel (gonadorelin HCI for subcutaneous or IV injection), Physician's Desk Reference, 50th Edition, pp. 2877–2878 Powell, et al., “Peptide Liquid Crystals: Inverse Correlation of Kinetic Formation and Thermodynamic Stability in Aque (1996). ous Solution”, Pharmaceutical Research, 11/9, pp. Lupron (leuprolide acetate for Subcutaneous injection), Phy 1352–1354 (1994). Powell, et al., “Parenteral Peptide Formulations: Chemical sician's Desk Reference, 50th Edition, pp. 2555-2556 and Physical Properties of Native Luteinizing Hormone-R- (1996). eleasing Hormone (LHRH) and Hydrophobic Analogues in Aqueous Solution”, Pharmaceutical Research, 8/10, pp. Lupron Depot (leuprolide acetate for depot Suspension), 1258–1263 (1991). Physician's Desk Reference, 50th Edition, pp. 2556-2562 Powers, et al., “Solution Behavior of Leuprolide Acetate, an (1996). LHRH Agonist, as Determined by Circular Dichroism Spec troscopy”, Intl. J. of Pharmaceutics, 108, pp. 49-55 (1994). Lutrepulse (gonadorelin acetate for IV injection), Physi Shi, et al., “Long-Tem Stability of Aqueous Solutions of cian's Desk Reference, 50th Edition, pp.980–982 (1996). Luteinizing Hormone-Releasing Hormone ASSessed by an In-Vitro Bioassay and Liquid Chromatography”, J. of Phar Zoladex (goserelin acetate implant), Physician's Desk Ref maceutical Sciences, 73/6, pp. 819-821 (1984). erence, 50th Edition, pp. 2858–2861 (1996). U.S. Patent Jun. 29, 1999 Sheet 1 of 5 5,916,582 Peptide OO 1O.O 2O, O 3OO 4O.O Time (min) FIG. f. Mor Orner Fragments O. O 1O.O 2OO 30 O 40. O Time (min) FIG 2 U.S. Patent Jun. 29, 1999 Sheet 2 of 5 5,916,582 WOter y = 29.251 - 1.0543e-f- 4x R^2 = O. 985 S -2 Q-Q In kobs hao 3 S -3 S - 4 - 5 OOO28 OOO29 OOO3O OOO31 OOOJ2 OOO,55 o 2 Leuprolide S & 2 Cherrical S. 2 Di/Timer R o Moss Balance N NS Time (months) FIG. 4 U.S. Patent Jun. 29, 1999 Sheet 3 of 5 5,916,582 o 37C o 5OC S 65C s o 80C S. N N FIG. 5 Time (months) Long Term Stability - H2O/HDPE - 37C Chemical Stability Time (days) FIG. 6 U.S. Patent Jun. 29, 1999 Sheet 4 of 5 5,916,582 uOl) O Jueduo) Q Q 00|| 06 09 OZ 09 o7-H M?g peuluelep So Milung U.S. Patent Jun. 29, 1999 Sheet S of 5 5,916,582 .S. hu S (S s S S S & S 2, Oeuv 5,916,582 1 2 AQUEOUS FORMULATIONS OF PEPTIDES 22. “Pharmaceutical Manipulation of Leuprorelin Acetate to Improve Clinical Performance', H. Toguchi, J. Of Intl. CROSS-REFERENCE TO RELATED Medical Research, 18, pages 35-41 (1990). APPLICATIONS 23. “Long-Term Stability of Aqueous Solutions of Lutein 5 izing Hormone-Releasing Hormone ASSessed by an In-Vitro This application claims priority under 35 U.S.C. 119(e) to Bioassay and Liquid Chromatography', Y. F. Shi, R. J. U.S. application Ser. No. 60/021,199 filed Jul. 3, 1996, the Sherins, D. Brightwell, J. F. Gallelli, D. C. Chatterji, J. of disclosure of which is incorporated herein by reference. Pharmaceutical Sciences, 73/6, pages 819-821 (1984). FIELD OF THE INVENTION 24. “Peptide Liquid Crystals: Inverse Correlation of Kinetic Formation and Thermodynamic Stability in Aque This invention relates to Stable aqueous formulations of ous Solution', M. F. Powell, J. Fleitman, L. M. Sanders, V. peptide compounds at high concentrations. C. Si, Pharmaceutical Research, 11/9, pages 1352–1354 BACKGROUND OF THE INVENTION (1994). 25. “Solution Behavior of Leuprolide Acetate, an LHRH References Agonist, as Determined by Circular Dichroism 15 Spectroscopy”, M. E. Powers, A. Adejei, M.Y. Fu Lu, M. C. The following references are referred to by numbers in Manning, Intl. J. of Pharmaceutics, 108, pages 49-55 brackets () at the relevant portion of the specification. (1994). 1. Zoladex (goserelin acetate implant), Physician's Desk 26. “Preparation of Three-Month Depot Injectable Micro Reference, 50th Edition, pages 2858-2861 (1996). Spheres of Leuprorelin Acetate Using Biodegradable 2. U.S. Pat. No. 3,914,412, issued Oct. 21, 1975. Polymers”, Pharmaceutical Research, 11/8, pages U.S. Pat. No. 4,547,370, issued Oct. 15, 1985. 1143–1147 (1994). U.S. Pat. No. 4,661,472, issued Apr. 28, 1987. The disclosure of each of the above publications, patents or patent applications is hereby incorporated by reference in U.S. Pat. No. 4,689,396, issued Aug. 25, 1987. its entirety to the same extent as if the language of each U.S. Pat. No. 4,851,385, issued Jul. 25, 1989. 25 individual publication, patent and patent application were U.S. Pat. No. 5,198,533, issued Mar. 30, 1993. Specifically and individually incorporated by reference. U.S. Pat. No. 5,480,868, issued Jan. 2, 1996. Luteinizing hormone-releasing hormone (LHRH), also WO92/20711, published Nov. 26, 1992. known as gonadotropin releasing hormone (GnRH), is a 10. WO95/00168, published Jan. 5, 1995. decapeptide with the Structure: 11. WO95/04540, published Feb. 16, 1995. 12. "Stability of Gonadorelin and Triptorelin in Aqueous pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH. Solution”, V. J. Helm, B. W. Muller, Pharmaceutical Research, 7/12, pages 1253–1256 (1990). It is Secreted by the hypothalamus and binds to receptors on 13. “New Degradation Product of Des-Gly-NH-LH the pituitary gland, releasing luteinizing hormone (LH) and RH-Ethylamide (Fertirelin) in Aqueous Solution”, J. Okada, 35 follicle stimulating hormone (FSH). LH and FSH stimulate T. Seo, F. Kasahara, K. Takeda, S. Kondo, J. of Pharma the gonads to Synthesize Steroid hormones. Numerous ana ceutical Sciences, 80/2, pages 167-170 (1991). logs of LHRH are known, including peptides related to 14. “Characterization of the Solution Degradation Product LHRH which act as agonists and those which act as antago of Histrelin, a Gonadotropin Releasing Hormone (LHRH) nists. 1-15 LHRH analogs are known to be useful for Agonist”, A. R. Oyler, R. E. Naldi, J. R. Lloyd, D. A. 40 treating hormone-dependent diseaseS Such as prostate Graden, C. J. Shaw, M. L. Cotter, J. of Pharmaceutical cancer, benign proStato megaly, endome triosis, Sciences, 80/3, pages 271-275 (1991). hysteromyoma, metrofibroma, precocious puberty, or mam 15. “Parenteral Peptide Formulations: Chemical and mary cancer and as contraceptives. 8. Sustained release Physical Properties of Native Luteinizing Hormone administration is preferred for both agonist LHRH-related Releasing Hormone (LHRH) and Hydrophobic Analogues 45 compounds, which reduce the number of available receptors in Aqueous Solution”, M.
Load more

Recommended publications
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Fully Automated Dried Blood Spot Sample Preparation Enables the Detection of Lower Molecular Mass Peptide and Non-Peptide Doping Agents by Means of LC-HRMS
    Analytical and Bioanalytical Chemistry (2020) 412:3765–3777 https://doi.org/10.1007/s00216-020-02634-4 RESEARCH PAPER Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Tobias Lange1 & Andreas Thomas1 & Katja Walpurgis1 & Mario Thevis1,2 Received: 10 December 2019 /Revised: 26 March 2020 /Accepted: 31 March 2020 # The Author(s) 2020 Abstract The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), argu- ably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters.
    [Show full text]
  • Altered Cognitive Function in Men Treated for Prostate
    Altered Cognitive Function in Men Treated for Prostate Cancer with LHRH Analogues and Cyproterone Acetate: A Randomised Controlled Trial H. J. Green PhD1,2, K. I. Pakenham PhD1, B. C. Headley PhD3, J. Yaxley FRACS3, D. L. Nicol FRACS2,4, P. N. Mactaggart FRACS2,5, C. Swanson PhD2, R. B. W atson FRACS6, & R. A. Gardiner MD2,3 1School of Psychology and 2Department of Surgery, The University of Queensland, 3Royal Brisbane, 4Princess Alexandra, 5Queen Elizabeth II & 6Mater Hospitals, Brisbane, Queensland, Australia In conjunction with the Northern Section of the Urological Society of Australasia Correspondence should be addressed to: Dr R. A. Gardiner, Department of Surgery, The University of Queensland, Brisbane, Qld 4072, Australia Fax: +61 7 3365 5559; Phone: +61 7 3365 5233; Email: f.gardiner@ mailbox.uq.edu.au This work was wholly funded by Queensland Cancer Fund. **PREPRINT. Final version published in British Journal of Urology (BJU: International) (2002), 90, 427-432 ** Short Title: COGNITIVE CHANGES W ITH HORMONAL MEDICATION 2 Objective. Luteinising hormone releasing hormone (LHRH) analogues have been associated with memory impairments in women using these drugs for gynaecological conditions. This is the first systematic investigation of the cognitive effects of LHRH analogues in male patients. Methods. 82 men with non-localised prostate cancer were randomly assigned to receive continuous leuprorelin (LHRH analogue), goserelin (LHRH analogue), cyproterone acetate (steroidal antiandrogen) or close clinical monitoring. These patients underwent cognitive assessments at baseline and before commencement of treatment (77) then 6 months later (65). Results. Compared with baseline assessments, men administered androgen suppression monotherapy performed worse in 2/12 tests of attention and memory.
    [Show full text]
  • The Use of an Intravaginal Triptorelin Gel to Induce Ovulation in the Mare
    THE USE OF AN INTRAVAGINAL TRIPTORELIN GEL TO INDUCE OVULATION IN THE MARE by CHELSEA D. SINCLAIR B.S., Clemson University, 2013 A THESIS submitted in partial fulfillment of the requirements for the degree MASTER OF SCIENCE Department of Animal Sciences and Industry College of Agriculture KANSAS STATE UNIVERSITY Manhattan, Kansas 2016 Approved by: Major Professor Dr. Joann M. Kouba Copyright CHELSEA D. SINCLAIR 2016 Abstract The objective of these studies was to investigate the efficacy of an intravaginal triptorelin acetate (TA) gel as an ovulation-inducing agent in mares. In Exp 1, 24 mares were stratified by parity and age and randomly assigned to 3 treatment groups receiving either: 5 mL TA gel (500 μg TA; TA5), 10 mL TA gel (1,000 μg TA; TA10), or 5 mL vehicle gel only (CON). Following the appearance of a follicle ≥ 25 mm, blood samples were obtained every 24 h until treatment administration for measurement of luteinizing hormone (LH) concentrations. Once a follicle ≥ 35 mm in diameter was detected, treatment was administered intravaginally. Following treatment, blood samples were collected and ovaries were scanned via transrectal ultrasonography every 12 h until 48 h post-ovulation. Both TA5 and TA10 tended (P = 0.08) to experience a brief surge in LH by 12 h post-treatment. Regarding LH concentrations, there was a significant (P < 0.005) treatment by time interaction. The interval from treatment to ovulation was not different (P > 0.05) between groups, nor was there a difference (P > 0.05) in the percentage of mares ovulating within 48 h of treatment administration.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson Et Al
    US006235.712B1 (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson et al. (45) Date of Patent: May 22, 2001 (54) NON-AQUEOUS POLARAPROTIC PEPTIDE Helm, et al., “Stability of Gonadorelin and Triptorelin in FORMULATIONS Aqueous Solution”, Pharm. Res., 7/12, pp. 1253-1256 (1990). (75) Inventors: Cynthia L. Stevenson; Steven J. Johnson, et al., “Degradation of the LH-RHAnalog Nafare Prestrelski, both of Mountain View, CA lin Acetate in Aqueous Solution”, Intl. J. Pharm., 31, pp. (US) 125-129 (1986). 73) Assignee:9. ALZA Corporation,p Mountain View, Lupron (leuprolide acetate for Subcutaneous injection), Phy CA (US) sician's Desk Ref, 50th Ed., pp. 2555-2556 (1996). Lupron Depot (leuprolide acetate for depot Suspension), * ) Notice: Subject to anyy disclaimer, the term of this Physician's Desk Ref, 50th Ed., pp. 2556-2562 (1996). patent is extended or adjusted under 35 Lutrepulse (gonadorelin acetate for IV injection), Physi U.S.C. 154(b) by 0 days. cian's Desk Ref, 50th Ed., pp.980–982 (1996). Okada, et al., “New Degradation Product of (21) Appl. No.: 09/514,951 Des-Gly'-NH-LH-RH-Ethylamide (Fertirelin) in Aque (22) Filed: Feb. 28, 2000 ous Solution”, J. Pharm. Sci., 80/2, pp. 167–170 (1991). Okada, et al., “Preparation of Three-Month Depot Injectable Related U.S. Application Data MicroSpheres of Leuprorelin Acetate Using Biodegradable Polymers”, Pharm. Res., 11/8, pp. 1143–1147 (1994). (62) Division of application No. 09/293,839, filed on Apr. 19, 1999, now Pat. No. 6,124,261, which is a continuation of Oyler, et al., “Characterization of the Solution Degradation application No.
    [Show full text]
  • Goserelin (Zoladex)
    Goserelin (Zoladex) This booklet explains what goserelin is, when it may be prescribed, how it works and what side effects may occur. Goserelin is the generic (non‑branded) name of the drug and how it’s referred to in this booklet. Its current brand name is Zoladex. This information is by Breast Cancer Care. We are the only specialist UK‑wide charity that supports people affected by breast cancer. We’ve been supporting them, their family and friends and campaigning on their behalf since 1973. Today, we continue to offer reliable information and personal support, over the phone and online, from nurses and people who’ve been there. We also offer local support across the UK. From the moment you notice something isn’t right, through to treatment and beyond, we’re here to help you feel more in control. For breast cancer care, support and information, call us free on 0808 800 6000 or visit breastcancercare.org.uk Visit breastcancercare.org.uk 3 What is goserelin? Goserelin is a type of hormone therapy used to treat breast cancer in pre-menopausal women (women who have not been through the menopause). It is given as an injection into the abdomen (belly). It can also be used to try to preserve fertility during chemotherapy (see page 4). Goserelin as a treatment for breast cancer How does it work? Some breast cancers are stimulated to grow by the hormone oestrogen. Before the menopause, oestrogen is mainly produced in the ovaries. Goserelin switches off this production by interfering with hormone signals from the brain that control how the ovaries work.
    [Show full text]
  • Triptorelin, Goserelin and Leuprorelin for Prostate
    789FM.1 GONADORELIN ANALOGUES (GnRHa): TRIPTORELIN, GOSERELIN, LEUPRORELIN FOR PROSTATE CANCER - AMBER RECOMMENDATION GUIDELINE This guideline provides prescribing and monitoring guidance for triptorelin, goserelin and Leuprorelin use in prostate cancer. It should be read in conjunction with the Summary of Product Characteristics (SPC), available on www.medicines.org.uk/emc, and the BNF. BACKGROUND AND INDICATIONS FOR USE There is no conclusive evidence to suggest that any one GnRHa is more effective or has fewer side effects than another for the treatment of prostate cancer.5, 7-9 Available evidence suggests that GnRHa are similar in effectiveness to surgical castration. They have the same licensed indications in the treatment of prostate cancer (Appendix 1). Appendix 2 compares doses, administration frequency and costs.1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is the 1st choice GnRHa for treatment of metastatic prostate cancer patients on life-long treatment on the Bucks formulary. This is because it is: • Administered via a smaller sized needle (20 gauge) compared to goserelin LA 10.8 mg (14 gauge), thus minimising discomfort to patients.9 • The least expensive in terms of drug and administration costs (Appendix 2).1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is not preferred in: • Patients newly initiated GnRHa because the first dose should be a monthly preparation (Decapeptyl® SR 3 mg) in order to check that the product is tolerated prior to changing to the six monthly preparation.14 • Anticoagulated patients. This is because triptorelin is an intramuscular (IM) injection. Subcutaneously administered GnRHa (goserelin or leuprorelin) may be preferable.9 RESPONSIBILITIES Hospital specialist 1.
    [Show full text]
  • Reproductionresearch
    REPRODUCTIONRESEARCH Relationships between FSH patterns and follicular dynamics and the temporal associations among hormones in natural and GnRH-induced gonadotropin surges in heifers J M Haughian, O J Ginther1,KKot1 and M C Wiltbank Department of Dairy Science, 1675 Observatory Drive and 1Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison, Wisconsin 53706, USA Correspondence should be addressed to M C Wiltbank; Email: [email protected] Abstract Preovulatory LH and FSH surges and the subsequent periovulatory FSH surge were studied in heifers treated with a single injection of GnRH (100 mg, n 5 6) or saline (n 5 7). Blood samples were collected every hour from 6 h before treatment until 12 h after the largest follicle reached $8.5 mm (expected beginning of follicular deviation). The GnRH-induced preovulatory LH and FSH surges were higher at the peak and shorter in duration than in controls, but the area under the curve was not different between groups. The profiles of the preovulatory LH and FSH surges were similar within each treatment group, suggesting that the two surges involved a common GnRH-dependent mechanism. Concentrations of FSH in controls at the nadir before the preovulatory surge and at the beginning and end of the periovulatory surge were not significantly different among the three nadirs. A relationship between variability in the periovulatory FSH surge and number of 5.0 mm follicles was shown by lower FSH concentrations during 12–48 h after the beginning of the surge in heifers with more follicles (11.0 6 1.0 follicles (mean6S.E.M.) n 5 7) than in heifers with fewer follicles (5.7 6 0.4, n 5 6).
    [Show full text]
  • Investigation of the Presence of Gnrh and Gnrh-R System in Bovine
    Investigation of the Presence of GnRH and GnRH-R System in Bovine Oocytes, Sperm and Early Embryos and their Functional Role in Reproduction by USWATTELIYANARALALAGE FELICIA RUWANIE PERERA B.V.Sc., University of Peradeniya, Peradeniya, Sri Lanka, 2001 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Animal Science) THE UNIVERSITY OF BRITISH COLUMBIA (VANCOUVER) April 2010 ©Uswatteliyanaralalage Felicia Ruwanie Perera, 2010 ABSTRACT The objectives of this study were to investigate: 1) the effect of GnRH agonist on oocyte maturation, sperm function and fertilization, 2) the presence of GnRH-R in bovine oocytes, sperm and early embryos. To examine the effect of GnRH agonist on sperm function, sperm were incubated in modified Tyrode’s medium with 0, 0.2, 0.4, 0.8 and 1.2 µgmL -1 of buserelin and with1 -1 µgmL P4 for 3 h. Acrosome status in each group was assessed at 0 h and 3 h. For zona- binding assay, in vitro matured oocytes were co-incubated with sperm in different concentrations of buserelin and P 4 for 4 h and the zona-bound sperm in each treatment group was determined. Acrosome reacted percentage were higher in sperm treated with 0.4, 0.8 µgmL -1 buserelin than the control group (p<0.001). The number of zona-bound sperm were higher in 0.8 µgmL -1 buserelin compared to negative control (p<0.01). Effect of buserelin was blocked by antide. To investigate the effect of GnRHa on maturation of bovine oocytes 0.8 µgmL -1 buserelin was added to the in vitro maturation media and maturation rate was obtained after 24 h against control groups with FSH and without FSH.
    [Show full text]
  • Reproductive Endocrinology of the Dog
    Reproductive endocrinology of the dog Effects of medical and surgical intervention Jeffrey de Gier 2011 Cover: Anjolieke Dertien, Multimedia; photos: Jeffrey de Gier Lay-out: Nicole Nijhuis, Gildeprint Drukkerijen, Enschede Printing: Gildeprint Drukkerijen, Enschede De Gier, J., Reproductive endocrinology of the dog, effects of medical and surgical intervention, PhD thesis, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands Copyright © 2011 J. de Gier, Utrecht, The Netherlands ISBN: 978-90-393-5687-6 Correspondence and requests for reprints: [email protected] Reproductive endocrinology of the dog Effects of medical and surgical intervention Endocrinologie van de voortplanting van de hond Effecten van medicamenteus en chirurgisch ingrijpen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 20 december 2011 des middags te 12.45 uur door Jeffrey de Gier geboren op 14 mei 1973 te ’s-Gravenhage Promotor: Prof.dr. J. Rothuizen Co-promotoren: Dr. H.S. Kooistra Dr. A.C. Schaefers-Okkens Publication of this thesis was made possible by the generous financial support of: AUV Dierenartsencoöperatie Boehringer Ingelheim B.V. Dechra Veterinary Products B.V. J.E. Jurriaanse Stichting Merial B.V. MSD Animal Health Novartis Consumer Health B.V. Royal Canin Nederland B.V. Virbac Nederland B.V. Voor mijn ouders
    [Show full text]